In FY2017, the CDC’s viral hepatitis programs received only $34 million. Funding levels have long been insufficient to combat the growing number of viral hepatitis cases in the country. It is imperative that we act on the urgent need for additional federal funding and respond to the recent explosion of opioid use in the United States that has fueled increases in new hepatitis B, hepatitis C, and HIV infections.
Panelists will provide an introduction to the federal budget and appropriations process, an overview of appropriations advocacy strategies, and updates on coalition-based efforts to advocate for increased funding and support for viral hepatitis programs in the United States.
Moderator: Rhea Racho, Public Policy and Program Manager, Hepatitis B Foundation
Speakers: Emily McCloskey, Associate Director, Policy & Legislative Affairs, the National Alliance for State and Territorial AIDS Directors (NASTAD) Frank Hood, Hepatitis C Policy Associate, The AIDS Institute